Insights Advancing the Future of Pharmaceuticals

Equinox Group specializes in assessing the commercial potential of drug programs in all stages of R&D, delivering quantitative insights in disease area strategy, market access, patient share forecasting, patient flow, and epidemiology.

Explore Our Tools
Schedule a Demo
Years of Experience
30+
Drug Assessments
1,000+

Decision Support at Every Stage of the Product Lifecycle

Disease Area Strategy

Find out which indications offer the best commercial opportunities and how to prioritize them

BD & Early R&D

Assess an asset's Clinical Innovation and peak share potential, whether evaluating a BD&L opportunity or developing a TPP

Late-Stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

Compare All Offerings

The framework at the heart of our analysis and how we use it to predict patient share

The Unmet Need Framework

1 Characterize the Unmet Need

2 Measure the Clinical Innovation

Comparison table showing different metrics for Product X and Product Y, including unmet need score, relative unmet need improvement, competitive intensity rating, diagnosed prevalence, annual cost of regimen, and projected peak patient share.

3 Predict Share

See the framework in detail →

Recent Articles

Our Insights
Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC
Oncology
Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC
Oncology
Read more →
Oncology
BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more
Oncology
BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more
Oncology
Read more →
Oncology
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Disease
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Disease
Read more →
Chronic Disease
Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved
Oncology
Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved
Oncology
Read more →
Oncology
Lipfendra Brings PCSK9i Efficacy with Oral Convenience
Chronic Disease
Lipfendra Brings PCSK9i Efficacy with Oral Convenience
Chronic Disease
Read more →
Chronic Disease
Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care
Oncology
Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care
Oncology
Read more →
Oncology
TROP2 ADCs: A Major Innovation for 1L TNBC
Oncology
TROP2 ADCs: A Major Innovation for 1L TNBC
Oncology
Read more →
Oncology
TP53, the most altered gene in oncology
Oncology
TP53, the most altered gene in oncology
Oncology
Read more →
Oncology
Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality
Oncology
Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality
Oncology
Read more →
Oncology
Oveporexton Could be a Game-changer for Narcolepsy Type 1
Chronic Disease
Oveporexton Could be a Game-changer for Narcolepsy Type 1
Chronic Disease
Read more →
Chronic Disease

Want to get in touch?

Click here